Shin Hyun-Young, Park Sohee, Lee Ji Won
a Department of Family Medicine, Myongji Hospital, Seonam University, College of Medicine , Gyeonggi-do Republic of Korea.
b Department of Biostatistics, Graduate School of Public Health, Yonsei University , Seoul , Korea.
Endocr Res. 2017 Nov;42(4):287-295. doi: 10.1080/07435800.2017.1300808. Epub 2017 Mar 21.
Adiponectin and chemerin have been reported their associations with insulin resistance and chronic inflammation. However, the relationship between adiponectin and chemerin themselves has not been fully elucidated. Therefore, we investigated the effects of changes in adiponectin and chemerin levels after a weight intervention.
We recruited 136 healthy overweight or obese subjects from 2006 to 2009 and provided all participants lifestyle modification therapy with diet consultations over 16 weeks. We assigned the participants to take orlistat or sibutramine or to a no prescription group. We analyzed the data using paired t-tests, Pearson's partial correlation analysis, and stepwise multiple linear regression analysis.
∆ in chemerin was positively correlated with ∆ in adiponectin (r = 0.29, p < 0.01), and these trends were similar in the insulin-resistant (r = 0.35, p = 0.03) and insulin-sensitive (r = 0.27, p < 0.01) groups. In multiple regression analyses, Δadiponectin, ΔQUICKI (quantitative insulin-sensitivity check index), Δglucose, and ΔDBP were significantly associated with Δchemerin in the insulin-resistant group, and initial chemerin level, ΔQUICKI, ΔBMI (body mass index), and taking orlistat were associated with Δchemerin in the insulin-sensitive group.
Changes in chemerin levels were positively associated with changes in adiponectin levels. The association between these changes might be related to chemerin's dual inflammatory and anti-inflammatory effects or insulin resistance and insulin sensitivity enhancing effects, depending on the metabolic conditions. Additional studies are needed to clarify the mechanisms that underlie the effects of adiponectin and chemerin.
脂联素和趋化素已被报道与胰岛素抵抗和慢性炎症有关。然而,脂联素和趋化素之间的关系尚未完全阐明。因此,我们研究了体重干预后脂联素和趋化素水平变化的影响。
我们在2006年至2009年招募了136名健康的超重或肥胖受试者,并为所有参与者提供了为期16周的饮食咨询生活方式改善疗法。我们将参与者分为服用奥利司他或西布曲明组或非处方组。我们使用配对t检验、Pearson偏相关分析和逐步多元线性回归分析来分析数据。
趋化素的变化与脂联素的变化呈正相关(r = 0.29,p < 0.01),在胰岛素抵抗组(r = 0.35,p = 0.03)和胰岛素敏感组(r = 0.27,p < 0.01)中这些趋势相似。在多元回归分析中,胰岛素抵抗组中脂联素变化量、QUICKI(定量胰岛素敏感性检查指数)变化量、血糖变化量和舒张压变化量与趋化素变化量显著相关,胰岛素敏感组中初始趋化素水平、QUICKI变化量、BMI(体重指数)变化量和服用奥利司他与趋化素变化量相关。
趋化素水平的变化与脂联素水平的变化呈正相关。这些变化之间的关联可能与趋化素的双重促炎和抗炎作用或胰岛素抵抗及胰岛素敏感性增强作用有关,具体取决于代谢状况。需要进一步研究以阐明脂联素和趋化素作用的潜在机制。